{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-029639","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.690890+00:00","generated_at":"2026-05-23T19:06:06.664161+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Onconetix signs LOI for business combination with Ocuvex; Ocuvex holders to own ~90%","bullets":["Non-binding LOI with Ocuvex Therapeutics, a private ophthalmic biopharma company with FDA-approved product and late-stage clinical assets.","Upon closing, Onconetix will issue new shares to acquire all Ocuvex equity; Ocuvex holders to own ~90% of combined company.","Transaction subject to due diligence, definitive agreement, financing, regulatory and stockholder approvals; no assurance of completion.","Onconetix Chairman Andrew J. Oakley states combination will 'immediately expand our reach beyond oncology, enhancing shareholder value.'","Ocuvex President/CEO Anthony W. Amato notes combining will 'broaden access to capital.'"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-029639","json":"https://secwatch.observer/filing/0001213900-25-029639.json","markdown":"https://secwatch.observer/filing/0001213900-25-029639.md","text":"https://secwatch.observer/filing/0001213900-25-029639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/0001213900-25-029639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/ea0237471-8k_oncon.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:06:06.664161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}